Can Graves disease cause cessation of menstrual periods (amenorrhea) in women of reproductive age?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Graves Disease Cause Amenorrhea?

Yes, Graves disease can cause menstrual periods to stop (amenorrhea), but this occurs primarily in cases of severe, untreated hyperthyroidism and is actually less common than historically believed.

Prevalence and Severity Relationship

The relationship between Graves disease and amenorrhea is directly tied to disease severity:

  • Severe hyperthyroidism shows a 2.5% prevalence of secondary amenorrhea, compared to only 0.2% in mild-moderate cases 1
  • Overall menstrual disturbances occur in approximately 21.5% of thyrotoxic patients, with the majority (78.5%) maintaining regular cycles 2
  • True amenorrhea is notably rare—one large study found no patients presented with complete amenorrhea among 214 premenopausal women with thyrotoxicosis 2

Clinical Pattern and Mechanism

When menstrual changes do occur in Graves disease, they typically manifest as:

  • Hypomenorrhea (light periods): 3.7% in severe cases vs 0.9% in mild-moderate disease 1
  • Oligomenorrhea (infrequent periods): more common than complete cessation
  • Secondary amenorrhea: rare, occurring in 2.5% of severe cases 1

The mechanism involves reversible suppression of gonadotropins (LH and FSH), which has been documented in severe Graves disease and normalizes with treatment 3. Higher free T4 levels correlate with increased menstrual irregularities, particularly in smokers 2.

Important Clinical Caveats

Smoking significantly amplifies risk: Among patients with menstrual disturbances, 50% were smokers versus only 19% of those with normal periods (p<0.001) 2. Higher T4 levels were observed in smokers with irregular periods compared to non-smokers 2.

Treatment restores normal function: The gonadotropin suppression and menstrual irregularities are reversible with achievement of euthyroid status 3. This underscores the importance of prompt diagnosis and treatment.

Long-term autoimmune effects: Women with Graves disease face an 89% higher risk of amenorrhea and 2.40-fold higher risk of infertility due to ovarian failure compared to controls, suggesting thyroid autoimmunity may affect ovarian reserve beyond acute hyperthyroidism 4.

Practical Management Approach

When evaluating amenorrhea in a woman with known or suspected Graves disease:

  1. Assess hyperthyroidism severity through free T4 and T3 levels—higher values correlate with menstrual dysfunction 1, 2
  2. Document smoking status as this independently worsens menstrual irregularities 2
  3. Initiate appropriate thyroid treatment (antithyroid drugs, radioactive iodine, or surgery per guidelines 5)
  4. Monitor for restoration of menses with achievement of euthyroid status
  5. Consider ovarian reserve testing in women planning future pregnancy, given the association between thyroid autoimmunity and premature ovarian insufficiency 4

The key message: while Graves disease can cause amenorrhea, it is uncommon and primarily occurs with severe, untreated disease. Restoration of euthyroid status typically resolves menstrual dysfunction, making prompt treatment essential for both thyroid and reproductive health outcomes.

References

Research

Menstrual disturbances in thyrotoxicosis.

Clinical endocrinology, 1994

Research

Decreased secretion of gonadotropins in a patient with Graves' disease.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 1996

Guideline

treatment of adult graves' disease.

Annales d'endocrinologie, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.